Pipeline

Data from the latest pre-clinical animal in vivo study demonstrated statistically significant improvements in several key measures relevant to the development and progression of NASH including:

  • Cenicriviroc (40 mg/kg, QID) both a positive control and comparator arm in the study showed a 1.5 point drop in the NAFLD/NAS score vs controls (p<0.01) and 54.1% (p<0.0001) reduction in fibrosis area compared to controls as measured by Sirius Red staining.
  • NP-135 (200 mg/kg, QID) showed a 1.1 point drop in the NAFLD/NAS score vs controls (p>0.05) and a 84.4% reduction (p<0.0001) in fibrosis area.
  • NP-135 also showed significant anti-fibrotic activity in a unilateral urinary obstruction (UUO) model of chronic kidney disease (CKD), reducing fibrosis by 52.1% (p<0.000001).

Data from the latest pre-clinical animal in vivo study demonstrated that clinically relevant doses resulted in statistically significant improvements in the reduction in fibrosis in the UUO model as measured by Sirius Red staining over untreated controls:

  • Telmisartan (3mg/kg), a positive control, reduced fibrosis by 32.6% (p<0.001).
  • Cenicriviroc (40 mg/kg) a CCR2/5 chemokine receptor antagonist with reported anti-fibrotic activity, reduced fibrosis by 31.9% (p=0.00032).
  • NP-160 (40 mg/kg) reduced fibrosis by 57.6% (p <0.000001). NP-160 was also previously reported to be anti-fibrotic in a mouse model of non-alcoholic steatohepatitis (NASH).
Crohn’s

Data from the latest pre-clinical animal in vivo study demonstrated statistically significant improvements in multiple measurements over multiple time points relevant to CD including:

  • Body weight (p<0.001), occult positivity (p<0.05), colon weight (p<0.05), colon length (p<0.001) and the colon weight/length ratio (p<0.001).
  • NP-178 compared very favourably to the control, 5-ASA, the current standard of care for IBD.
  • No negative side effects were observed.
Colitis:

Data from the latest pre-clinical animal in vivo study demonstrated statistically significant improvements in multiple measurements over multiple time points relevant to ulcerative colitis including:

  • Body weight, stool consistency, colon length and weight ratios and occult positivity (p<0.001 to p<0.05).
  • NP-178 compared very favourably to the control, 5-ASA, the current standard of care for IBD.
  • No negative side effects were observed.